Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alaunos Therapeutics Inc TCRT

Healthcare Biotechnology
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity... see more

Recent & Breaking News (NDAQ:TCRT)

ZIOPHARM to Present at the Jefferies 2nd Annual Immuno-Oncology Summit

GlobeNewswire March 31, 2016

Molecular Therapy Publication Highlights Sleeping Beauty Potential in Personalized TCR Gene Therapy

GlobeNewswire March 9, 2016

ZIOPHARM Reports Fourth-Quarter 2015 Financial Results and Provides Update on Recent Activities

GlobeNewswire February 24, 2016

ZIOPHARM Announces First Patient Treated in the Dose Escalation Portion of the Phase 1 Study of Ad-RTS-hIL-12 for Advanced Glioma

GlobeNewswire February 24, 2016

ZIOPHARM Announces Publication in Scientific Reports Describing Genetic Editing of Human Leukocyte Antigen in Cell Therapies to Broaden Their Human Application

GlobeNewswire February 23, 2016

ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies

GlobeNewswire February 9, 2016

ZIOPHARM to Present at the 18th Annual BIO CEO & Investor Conference

GlobeNewswire February 2, 2016

ZIOPHARM Announces Sleeping Beauty Non-Viral Gene Transfer Technology Featured in Nature Medicine

GlobeNewswire January 11, 2016

ZIOPHARM to Present at the 34th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2016

ZIOPHARM to Host Corporate Update and 2016 Outlook Conference Call on Wednesday, December 16, 2015 at 4:30 PM ET

GlobeNewswire December 11, 2015

ZIOPHARM Announces Presentation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients With Locally Advanced or Metastatic Breast Cancer at 2015 SABCS

GlobeNewswire December 10, 2015

Equity Price Movement at a Glance - Research on Express, ZIOPHARM Oncology, Ascena Retail Group and TASER International

Accesswire December 9, 2015

ZIOPHARM Announces Presentation of Data From CD19-Specific CAR+ T-Cell Therapy Programs at ASH Annual Meeting

GlobeNewswire December 7, 2015

ZIOPHARM Announces Data Highlighting Ad-RTS-hIL-12 Activity in Glioma at SNO

GlobeNewswire November 19, 2015

ZIOPHARM Reports Third-Quarter 2015 Financial Results and Recent Activities

GlobeNewswire November 2, 2015

Intrexon and ZIOPHARM to Develop Immunotherapies for Treatment of Graft-Versus-Host Disease

GlobeNewswire September 28, 2015

ZIOPHARM Appoints Scott Tarriff to Its Board of Directors

GlobeNewswire September 28, 2015

ZIOPHARM Announces Presentation of Clinical and Preclinical Data From Ad-RTS-IL-12 at CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference

GlobeNewswire September 18, 2015

ZIOPHARM to Present at the Wells Fargo 10th Annual Health Care Conference

GlobeNewswire September 3, 2015

ZIOPHARM Announces Cancer Research Publication of Study Demonstrating Preferential Targeting of Solid Tumor Cells by Modified CAR T Cells

GlobeNewswire September 1, 2015